Q32 Bio CSO sells 2,815 shares for tax withholding

Q32 Bio Inc. Chief Scientific Officer Shelia M. Violette reported an automatic sale of 2,815 shares of common stock on February 25, 2026 to cover tax withholding from vesting restricted stock units.

Accepted by SEC EDGAR 02/27/2026 - 07:00 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Q32 Bio Inc. Chief Scientific Officer Shelia M. Violette reported an automatic sale of 2,815 shares of common stock on February 25, 2026 to cover tax withholding from vesting restricted stock units. The weighted average sale price was $4.5144 per share, across trades between $4.35 and $4.69.

After this sale, she held 55,569 shares directly. An additional 36,277 shares were reported as held indirectly through Violette Holdings LLC, for which she disclaims beneficial ownership except for any pecuniary interest.

Insider Trade Summary

Net Seller: 2,815 shares

Net Sell 1 txn

Insider Violette Shelia M.

Role Chief Scientific Officer

Sold 2,815 shs ($13K)

Share of Position Sold 4.8%

Type	Security	Shares	Price	Value
Sale	Common Stock	2,815	$4.5144	$13K
Holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 55,569 shares (Direct); Common Stock — 36,277 shares (Indirect, By Violette Holdings LLC)

Holdings Before and After: Common Stock, 58,384 to 55,569 shares (Direct)

Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (3)

1. F1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.35 to $4.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
3. F3. Shares held by Violette Holdings LLC ("Violette Holdings"). The Reporting Person is a manager of Violette Holdings and disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Q32 Bio (QTTB) report for Shelia M. Violette?

Q32 Bio reported that Chief Scientific Officer Shelia M. Violette automatically sold 2,815 common shares on February 25, 2026. The sale covered tax withholding obligations tied to vesting restricted stock units, rather than a discretionary open-market portfolio decision.

At what price did Q32 Bio (QTTB) shares sell in this Form 4 filing?

The reported weighted average sale price was $4.5144 per Q32 Bio share. Trades occurred in multiple transactions between $4.35 and $4.69, and detailed price breakdowns are available on request from the company, any security holder, or SEC staff.

How many Q32 Bio (QTTB) shares does Shelia M. Violette hold after the Form 4 sale?

After the tax-related sale, Shelia M. Violette directly held 55,569 Q32 Bio common shares. The filing also lists 36,277 additional shares held indirectly through Violette Holdings LLC, with beneficial ownership disclaimed except for any pecuniary interest.

Why were Q32 Bio (QTTB) shares sold in this insider transaction?

The shares were sold automatically to satisfy tax withholding obligations from vesting restricted stock units. This type of transaction typically occurs under predetermined instructions, meaning it was not an elective sale based on market views or personal portfolio changes.

What is Violette Holdings LLC’s role in Q32 Bio (QTTB) share ownership?

Violette Holdings LLC is reported as holding 36,277 Q32 Bio shares indirectly associated with Shelia M. Violette. She is a manager of the LLC but disclaims beneficial ownership of those shares except for any pecuniary interest, limiting how they are attributed to her personally.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Violette Shelia M.

(Last) (First) (Middle)

Q32 BIO INC.

830 WINTER STREET

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		S(1)		2,815	D	$4.5144(2)	55,569	D
Common Stock								36,277	I	By Violette Holdings LLC(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.35 to $4.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

3. Shares held by Violette Holdings LLC ("Violette Holdings"). The Reporting Person is a manager of Violette Holdings and disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.

	/s/ Eric Bell, Attorney-in-Fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.